Compare SKYE & WHF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SKYE | WHF |
|---|---|---|
| Founded | 2012 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance Companies |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.0M | 152.5M |
| IPO Year | 2013 | 2012 |
| Metric | SKYE | WHF |
|---|---|---|
| Price | $1.78 | $7.08 |
| Analyst Decision | Strong Buy | Sell |
| Analyst Count | 3 | 2 |
| Target Price | ★ $15.00 | $7.75 |
| AVG Volume (30 Days) | ★ 81.7K | 78.7K |
| Earning Date | 05-08-2026 | 05-07-2026 |
| Dividend Yield | N/A | ★ 13.67% |
| EPS Growth | N/A | ★ 31.91 |
| EPS | N/A | ★ 0.44 |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $16.76 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.26 | $6.07 |
| 52 Week High | $4.99 | $7.87 |
| Indicator | SKYE | WHF |
|---|---|---|
| Relative Strength Index (RSI) | 54.89 | 50.64 |
| Support Level | $1.64 | $7.08 |
| Resistance Level | $2.28 | $7.22 |
| Average True Range (ATR) | 0.22 | 0.18 |
| MACD | -0.07 | 0.00 |
| Stochastic Oscillator | 32.00 | 25.61 |
Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis, and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.
WhiteHorse Finance Inc is a non-diversified, closed-end management investment company. It makes debt investments in privately held; small-cap companies located in United States. Its investment objective is to generate risk-adjusted returns by originating and investing in senior secured loans, including first lien and second lien facilities, to performing lower middle market companies across a range of industries.